false0001269021 0001269021 2020-02-26 2020-02-26


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2020
 
Portola Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
001-35935
20-0216859
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
 
 
270 E. Grand Avenue
 

South San Francisco
California
94080
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (650) 246-7300
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock
 
PTLA
 
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.





Item 2.02 Results of Operations and Financial Condition
On February 26, 2020, Portola Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2019. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
 
 
 
Number
 
Description of Document
 
 
 
99.1
 
104
 
Inline XBRL for the cover page of this Current Report on Form 8-K.





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
Portola Pharmaceuticals, Inc.
Dated: February 26, 2020
 
 
 
 
 
By:
/s/ Mike Ouimette
 
 
 
Mike Ouimette
 
 
 
Vice President and Assistant Corporate Secretary, Legal



Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Apr 2020 to May 2020 Click Here for more Portola Pharmaceuticals Charts.
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From May 2019 to May 2020 Click Here for more Portola Pharmaceuticals Charts.